On the Fast Track

A US Food and Drug Administration initiative has sped the review and approval process for promising drugs, but researchers from Wake Forest University Medical School note in the Journal of the American Medical Association that some fast-tracked drugs have been associated with safety risks. Thomas Moore and Curt Furberg focus on three drugs — vandetanib, fingolimod, and dabigatran — that have been approved quickly despite some safety concerns and uncertainty regarding dosing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.